Your browser doesn't support javascript.
loading
Rapid ART initiation with bictegravir/emtricitabine/tenofovir alafenamide in individuals presenting with advanced HIV disease (Rainbow study).
Camici, Marta; Gagliardini, Roberta; Lanini, Simone; Del Duca, Giulia; Mondi, Annalisa; Ottou, Sandrine; Plazzi, Maria M; De Zottis, Federico; Pinnetti, Carmela; Vergori, Alessandra; Grilli, Elisabetta; Mastrorosa, Ilaria; Mazzotta, Valentina; Paulicelli, Jessica; Bellagamba, Rita; Cimini, Eleonora; Tartaglia, Eleonora; Notari, Stefania; Tempestilli, Massimo; Cicalini, Stefania; Amendola, Alessandra; Abbate, Isabella; Forbici, Federica; Fabeni, Lavinia; Girardi, Enrico; Vaia, Francesco; Maggi, Fabrizio; Antinori, Andrea.
Afiliação
  • Camici M; Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy. Electronic address: marta.camici@inmi.it.
  • Gagliardini R; Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.
  • Lanini S; Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.
  • Del Duca G; Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.
  • Mondi A; Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.
  • Ottou S; Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.
  • Plazzi MM; Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.
  • De Zottis F; Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.
  • Pinnetti C; Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.
  • Vergori A; Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.
  • Grilli E; Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.
  • Mastrorosa I; Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.
  • Mazzotta V; Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.
  • Paulicelli J; Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.
  • Bellagamba R; Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.
  • Cimini E; Laboratory of Cellular Immunology and Pharmacology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.
  • Tartaglia E; Laboratory of Cellular Immunology and Pharmacology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.
  • Notari S; Laboratory of Cellular Immunology and Pharmacology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.
  • Tempestilli M; Laboratory of Cellular Immunology and Pharmacology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.
  • Cicalini S; Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.
  • Amendola A; Laboratory of Virology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.
  • Abbate I; Laboratory of Virology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.
  • Forbici F; Laboratory of Virology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.
  • Fabeni L; Laboratory of Virology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.
  • Girardi E; Scientific Direction, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.
  • Vaia F; General Direction, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.
  • Maggi F; Laboratory of Virology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.
  • Antinori A; Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.
Int J Antimicrob Agents ; 63(1): 107049, 2024 Jan.
Article em En | MEDLINE | ID: mdl-38056572
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piperazinas / Infecções por HIV / Fármacos Anti-HIV / Alanina / Tenofovir / Amidas / Compostos Heterocíclicos com 3 Anéis Limite: Female / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piperazinas / Infecções por HIV / Fármacos Anti-HIV / Alanina / Tenofovir / Amidas / Compostos Heterocíclicos com 3 Anéis Limite: Female / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article